Development of and Progression of Overt Heart Failure in Nonobstructive Hypertrophic Cardiomyopathy

Yasmine L Hiemstra1, Philippe Debonnaire2, Erik W van Zwet3

  • 1Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Insights

Predictors of heart failure (HF) in hypertrophic cardiomyopathy (HC) include age, New York Heart Association class, left ventricular global longitudinal strain (GLS), and left atrial volume (LAVI). These factors, along with their changes over time, are associated with HF development in HC patients.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Heart Failure Research

Background:

  • Few studies identify heart failure (HF) predictors in hypertrophic cardiomyopathy (HC).
  • Natural progression of left ventricular (LV) abnormalities and HF association in HC are poorly understood.
  • Serial echocardiographic data in HC patients are limited.

Purpose of the Study:

  • Assess prognostic value of LV global longitudinal strain (GLS) and other factors for HF development in nonobstructive HC.
  • Correlate changes in echocardiographic parameters over time with HF development.
  • Investigate progression of LV abnormalities in HC.

Main Methods:

  • Echocardiography performed in 236 HC patients at baseline and during follow-up (6.5 years).
  • Endpoint: new HF development or progression to NYHA class III/IV.
  • Linear mixed model analysis for echocardiographic changes; multivariable Cox regression for predictors.

Main Results:

  • 40 patients reached the HF endpoint.
  • Independent HF predictors: age (HR 1.04), NYHA class (HR 2.30), GLS (HR 1.15), and LAVI (HR 2.22).
  • GLS and LAVI remained stable in non-HF patients but changed significantly in those who developed HF (p<0.05).

Conclusions:

  • LV dysfunction is progressive in nonobstructive HC, detectable by serial echocardiography.
  • Baseline GLS and LAVI, and their longitudinal changes, predict HF development.
  • Echocardiographic parameters offer prognostic value for HF in HC.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
496
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
952
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
983